One-pot stibine modified Co2(CO)8 catalyzed reductive N-alkylation of primary amides with carbonyl compounds
摘要:
A one-pot stibine modified Co-2(CO)(8) homogeneous catalytic reductive N-alkylation of primary amides using aldehydes/ketones as alkylating agents, is reported. Good to excellent yields of a wide range of secondary amides are obtained (up to 97%) under relative mild conditions. (C) 2012 Elsevier Ltd. All rights reserved.
[EN] 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS<br/>[FR] DERIVES DE 2-(6-AMINO-PYRIDINE-3-YL)-2-HYDROXYETHYLAMINE UTILISES COMME AGONISTES DES RECEPTEURS BETA 2-ADRENERGIQUES
申请人:PFIZER LTD
公开号:WO2004108676A1
公开(公告)日:2004-12-16
The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
[EN] COMPOUNDS HAVING BETA-AGONIST ACTIVITY<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE BETA-AGONISTE
申请人:PFIZER LTD
公开号:WO2005092841A1
公开(公告)日:2005-10-06
The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA
wherein R
1
, R
2
, R
3
and R
4
are as described in the specification.
[1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof
申请人:Masuda Akira
公开号:US20070010515A1
公开(公告)日:2007-01-11
Novel [1,2,4]triazolo[1,5-a]pyrimidine derivative of the general formula (1): (1) its prodrug or a pharmaceutically acceptable salt thereof, which exhibits an antigen presentation inhibiting activity and is useful as a preventive and/or therapeutic agent for immunological rejection and/or graft versus host reaction in organ/bone marrow transplant, autoimmune disease, allergic disease and/or inflammatory disease and also useful as an anticancer drug or as an immunological tolerance inducer for transplanted organ/transplanted bone marrow.